title: Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen.
authors.affiliation: Department of Virology, Bordeaux University Hospital, France.
authors.forename: I
authors.initials: I
authors.lastname: Pellegrin
authors.forename: I
authors.initials: I
authors.lastname: Garrigue
authors.forename: A
authors.initials: A
authors.lastname: Caumont
authors.forename: J L
authors.initials: JL
authors.lastname: Pellegrin
authors.forename: P
authors.initials: P
authors.lastname: Merel
authors.forename: M H
authors.initials: MH
authors.lastname: Schrive
authors.forename: P
authors.initials: P
authors.lastname: Bonot
authors.forename: H
authors.initials: H
authors.lastname: Fleury
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D017354:Point Mutation; D012367:RNA, Viral / Q000032:analysis; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use*; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D018119:Stavudine; D054303:HIV Reverse Transcriptase